Benzodiazepine Urine Immunoassay Reagent - Detection of Nordiazepam, Oxazepam, Temazepam, Lorazepam, and Alpha-Hydroxyalprazolam Abuse in Urine

The Naval Medical Logistics Command (NMLC) intends to establish a firm fixed price requirements contract on a sole source basis (IAW FAR 6.302-1) with the Microgenics Corporation, 46360 Fremont Boulevard, Fremont, California 94538, as the only source that can provide Benzodiazepine Reagent Kits to the Department of Defense (DoD) Drug Demand Reduction Program (DDRP) Laboratories. The laboratories include: Navy Drug Screening Laboratory (NDSL) Great Lakes, Illinois; NDSL Jacksonville, Florida; NDSL San Diego, California; Army Forensic Toxicology Drug Testing Laboratory (AFTDTL) Fort Meade, Maryland; AFTDTL Tripler Army Medical Center (AMC), Hawaii; Headquarters Air Force Drug Testing Laboratory (HQ AFDTL) Lackland Air Force Base, Texas; and Armed Forces Medical Examiner System (AFMES) Dover Air Force Base (AFB), Delaware.



Specifically, the Microgenics Corporation’s Cloned Enzyme Drug Immuno Assay (CEDIA) high sensitivity assay is the only commercially available immunoassay that includes B-glucuronidase and is compatible with the Hitachi Modular (D&P) Clinical Analyzers in use at the DoD DDRP Laboratories.

Microgenics is the only response source and no other supplies or services will satisfy agency requirements.



The proposed requirements contract shall have the following period of performance:



Base Period 01 March 2013 – 30 September 2013

Option Period 01: 01 October 2013 – 30 September 2014

Option Period 02: 01 October 2014 – 30 September 2015

Option Period 03: 01 October 2015 – 30 September 2016

Option Period 04: 01 October 2016 – 30 September 2017

Option Period 05: 01 October 2017 – 28 February 2018



This acquisition is being conducted in accordance with FAR Part 12 and FAR 16.5. There are no set-aside restrictions for this requirement. The intended procurement will be classified under North American Industry Classification System (NAICS) 325413 with a Small Business Size Standard of 500.

This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same service. All capability statements received within 15 days after publication of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.



Capability statements shall be submitted by email only as an MS Word or Adobe PDF attachment to Shannon Hess at Shannon.Hess@med.navy.mil (in subject line you shall reference: N62645-13-R-0012 Benzodiazepine Reagent Kits).

Statements are due no later than 06 January 2013, 04:30 PM local time. No phone calls accepted.